Background To be used optimally, new interventional devices ( When similar uncertainties existed for conventional balloon angioplasty, one approach to data collection and analysis was the National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty (NHLBI-PTCA) Registry. By collecting data on nearly 3000 angioplasty procedures performed between 1979 and 1981, this registry provided major understanding of the strengths and weaknesses of this new technique.3 When major changes in device design and patient selection ensued, NHLBI-PTCA Registry II was established to document these changes by collecting data on a second cohort of patients treated in 1985 through 1986 at a subset of original Registry sites. 4 The New Approaches to Coronary Intervention (NACI) Registry was established with funding from the NHLBI to extend the spirit of PTCA Registries I and II into the evaluation of several promising new devices. Since this promised to be an inherently more complex task than evaluating a single device such as conventional balloon angioplasty, it was clear that one task facing the NACI Registry would be the development of new standards for the collection, analysis, and reporting of the data relating to these new devices. 
Data Collection
As previously reported,5 data collection on each patient included a battery of forms containing a baseline form (describing patient history and clinical status), a procedure form (describing each target lesion and the sequence of devices used to treat it), and a device form (specifying the mode and reason for its use, the type of device failure [failure to cross the lesion, failure to improve the lesion, etc], and interim result present after use of each device). In addition, information regarding complications was collected both on the procedure form and on a hospital discharge form at the end of the admission. Although additional data on interim events were collected on various follow-up forms, this report is restricted to in-hospital events only.
By virtue of this modular form design and the use of standardized definitions of clinical and procedural terms documented in the NACI Manual of Operations, clinical coordinators at each site were able to successfully code all eligible procedures, regardless of technical complexity. Site readings of qualitative (thrombus, calcification, ulceration, etc) and quantitative lesion morphology (caliper-or computer-assisted measurements of absolute reference diameter, minimum lumen diameter, and lesion length) were also recorded on the NACI form set. Postdevice measurements were made from the last angiogram performed after that device was used but before any other device was used. Although a central Angiographic Core Laboratory (Washington Hospital Center) has now been established to overread all acute procedural films on patients in the NACI Registry, this report deals only with the site readings themselves.
Data Analysis
Data forms were transmitted by mail to the Coordinating Center at the University of Pittsburgh. Form inventories on incoming packets were prepared and correlated to procedure logs maintained at each participating center. When a complete set of forms was received on a given admission, the resulting data were entered into an IBM personal computer using the POP system and then uploaded into a VAX 6410 mainframe.
Descriptive statistics, including count data of discrete variables and the mean and SD of continuous variables, were compiled for this report using SAS. In comparisons of treatment groups, a value of P<.05 was taken as statistically significant.
Definitions of Success
Given the complexity of the procedures included in the Registry, various definitions of "success" might be applied with equal validity. Because the raw information on each procedure (including interim results after the use of each device) is contained in the modular NACI database, it is possible to retrospectively apply any number of such definitions to the primary data. The first level of success so investigated was device success. In common usage, device success may have several interpretations. All would require that the particular device be able to cross the target lesion, perform any specialized function (eg, cut tissue, be deployed, or deliver laser energy), and produce at least a minimal amount (20%) of reduction in diameter stenosis at the treatment site. While these criteria alone might constitute "device success" for a technology that seeks only to prepare a lesion for definitive balloon dilation, we elected to investigate a more stringent definition -that the device leave a residual stenosis 
Results

Analysis Set
The patient population consisted of 2835 patients (3201 lesions) treated with one of the participating devices, for whom complete in-hospital data had been submitted, entered, and analyzed before February 1993. As summarized in Table 1 (Tables  1 and 2) , it is still instructive to see how widely the specific outcomes discussed above vary from device to device, despite their high "success" rates reported in earlier publications.6-"11,4-20 While device success was >70% with DCA, ROTA, and both the PSS and GRS, it was <50% with TEC and the two ELCA devices (Table 3) . Adjunctive PTCA was used in more than 80% of all device procedures (except DCA, whose adjunctive PTCA rate was 46.4%), but there were major differences in whether this represented predilation (more common with the two stents) or postdilation (more common with ROTA, TEC, and ELCA devices).
With the use of adjunctive PTCA to improve suboptimal device results (a category that includes excessive residual stenosis, device failure, or even frank abrupt closure), the lesion success rate exceeded 80% for all devices studied and was in the 94% to 97% range for three devices (DCA, PSS, and ROTA Although conventional balloon angioplasty has proved increasingly safe and successful as a treatment for anatomically suitable patients with symptomatic coronary artery disease, it has continued to be limited by problems including (1) failure to cross total occlusions, (2) difficulty dilating calcified, eccentric, or diffuse lesions, (3) preventing or reversing abrupt closure, and (4) reducing or eliminating restenosis in the months after successful dilation.1"2'2",22 The recent spate of newer devices for coronary intervention reflects the hope that these devices will help overcome one or more of these ongoing limitations of conventional angioplasty and thus amplify the benefits of percutaneous transluminal revascularization as a whole. After an initial wave of unbridled enthusiasm, however, it became clear that none of these new devices were likely to replace balloon angioplasty, given the latter's broad anatomic and clinical applicability, high (90%) success rate, and low (<3%) incidence of major complications. Instead, current thinking favors the concept that these devices will generally be used in conjunction with balloon dilation and according to strategies that help to address one or more of the "niches" that remain problematic for conventional angioplasty alone.1"23 '24 The issue remains, however, about how best to establish the safety and efficacy of these new devices and to define their appropriate niches supported by a central data collection and analysis unit located at the University of Pittsburgh. To take into account the greater complexity of the new device procedures, however, a unique modular form design was developed that could be applied equally well to different device types and capture as much of the raw procedural data as possible.5 The driving idea behind this design was that it would then be possible to "reconstitute" the flow of the original procedure, to analyze the raw data according to various criteria as the understanding of device evaluation improved, and to report results without the vagaries inherent in the less precise definitions now in clinical use. It was also hoped that data available through the NACI Registry would help to identify specific lesion types for which two or more devices appeared to have favorable results (eg, focal lesions in saphenous vein grafts with a reference diameter >3 mm might be well suited to directional atherectomy or stent placement). So identified, these lesion and device types would be strong candidates for a formal randomized comparison. In this sense, the Registry does not function as a substitute for randomized trials. Instead, it serves as a way station between nonrandomized data collected on single devices by industry and investigator groups and the randomized trials that may be performed subsequently to compare new devices with each other or with conventional balloon angioplasty.
The NACI Registry has been successful in recruiting more than 3500 patients treated with one of the seven participating devices at 36 active sites with 97% baseline form compliance during the first 2 years of operation. Moreover, the modular form design has proved capable of recording even the most complex procedures, in which as many as six devices (including conventional balloon angioplasty) may be used sequentially to obtain the final result. As these data accrued, it became evident that the unique properties of the study devices and the constraints of their investigational protocols inevitably led their application to be concentrated in substantially different patient and lesion subsets, with marked differences in the mixture of planned and unplanned modes of use. These fundamental differences preclude direct comparison of any two devices unless patients are matched for those characteristics either by the performance of a randomized study or by restriction of the interdevice comparison to subsets selected for appropriate baseline characteristics. Defining 'Success'
This report is the first from the NACI Registry to look at the acute (in-hospital) results of the participat- ing new devices. We placed particular emphasis on applying several valid but distinct definitions of "success" and attempted to characterize the contribution of adjunctive conventional balloon angioplasty to the final outcome of new device treatment. In doing so, we have developed and applied three definitions of "success": (1) device success (analogous to PTCA success) was taken to mean the ability of the device to cross the target lesion, improve the diameter stenosis by 220%, and leave <50% residual stenosis; (2) lesion success refers to the ability (after use of the device plus any adjunctive angioplasty) to improve the stenosis by at least 20% and bring the final diameter stenosis below 50%; and (3) procedural success is a patient-based outcome that indicates that all lesions attempted with a new device were treated successfully and that the patient did not sustain a major complication (death, Q-wave myocardial infarction, or emergency bypass surgery).
The overall data from NACI showed high lesion (92.2%) and procedural (90.8%) success rates. Additionally, the residual diameter stenosis of 16 tP<.05, *P<.01, §P<.001. The data recorded in NACI were generally obtained early in the device development cycle, before premarket approval. As such, they may differ from the results obtained in general (postapproval) use, although data on device evolution and operator "learning curves" within NACI can be used to specify device design and operator experience.
6. The confidence intervals that surround our estimated acute results with the individual devices are widened by the fact that enrollment for all devices has not yet reached the specified target level of 500 cases per device. This situation should improve as enrollment for these devices continues.
Conclusions
Careful evaluation of new devices is critical to their optimal use. Single-center and multicenter (single-device) data are limited by the use of different analysis standards and definitions. Randomized trials comparing new devices with conventional balloon angioplasty are just beginning, and interdevice comparisons are still several years away, given that most devices have just received FDA approval. In the meantime, the NACI Registry may be a useful alternative source of information, since it contains detailed data on more than 3500 patients treated with one of seven new devices (three mechanical atherectomy catheters, two balloon-expandable stents, and two ablative lasers). Analysis of the first 2835 patients shows high overall lesion (92.2%) and procedural (90.8%) success rates with a low (4%) overall incidence of major complications (death, Q-wave myocardial infarction). This favorable outcome, however, was heavily dependent on the use of adjunctive balloon angioplasty (75.5% of cases), without which the "stand-alone" new-device success rate would have been only 66.5%. Given the major differences that existed between devices in terms of baseline clinical and angiographic characteristics as well as mode of use across devices, either randomized trials or carefully matched subset comparisons would be required before any differences in results could be ascribed to the devices themselves. These Registry data, however, provide unique insight into the current use of these new devices and their acute results. To the extent that matched subsets treated with two or more devices can be identified, NACI may help to identify lesion types in which subsequent randomized trials would be fruitful.
